Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention

NCT04806633 is registered in ClinicalTrials.gov with G.Gennimatas General Hospital as lead sponsor.

NCT NCT04806633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04806633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention
Lead sponsor
G.Gennimatas General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 1, 2021
Completion date
December 1, 2023
Enrollment
1,722 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, left cardiac catheterization, percutaneous coronary intervention, sodium-glucose co-transporter 2 inhibitors